DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022465/S-014, S-015, and S-016

SUPPLEMENT APPROVAL

Glaxo Wellcome Manufacturing Pte d/b/a GlaxoSmithKline
Attention: Thomas F. Kline
1250 South Collegeville Road
Collegeville, PA 19426

Dear Mr. Kline:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Votrient® (pazopanib) Tablets 200 mg and 400 mg:

Supplement #	Letter date	Received date
-014	July 11, 2012	July 11, 2012
-015	August 24, 2012	August 24, 2012
-016	February 28, 2013	February 28, 2013

We acknowledge receipt of your amendments:

Supplement #	Letter date	Received date
-014	September 6, 2012	September 6, 2012
	November 20, 2012	November 20, 2012
	November 30, 2012	November 30, 2012
	December 6, 2012	December 6, 2012
	January 3, 2013	January 3, 2013
	January 9, 2013	January 9, 2013
	January 31, 2013	January 31, 2013
-015	September 6, 2012	September 6, 2012
	November 20, 2012	November 20, 2012
	November 30, 2012	November 30, 2012
	December 6, 2012	December 6, 2012
	January 3, 2013	January 3, 2013
	January 9, 2013	January 9, 2013
	January 31, 2013	January 31, 2013

S-014: Prior Approval supplemental new drug application provides for the following revisions:

1. HIGHLIGHTS: editorial changes based on changes made in full prescribing information or for consistency with text in full prescribing information.

2. Section 2.2 – DOSAGE AND ADMINISTRATION: revisions to the "Concomitant Strong CYP3A4 Inhibitor" subsection to provide updated information.
3. Section 5.2, 5.5, 5.6, and 5.8 – WARNINGS AND PRECAUTIONS: editorial changes and correction of a mathematical error in the "QT prolongation and Torsades de Pointes subsection.
4. Section 6.1 – ADVERSE REACTIONS: addition of a "Bradycardia" subsection.
5. Section 7 – DRUG INTERACTIONS: addition of a "Drugs That Inhibit Transporters" subsection.
6. Section 12.3 – CLINICAL PHARMACOLOGY: revisions to the "Drug Interaction" subsection to provide updated information of co-administration with a strong CYP3A4 inhibitor.

SLR-015: Prior Approval supplemental new drug application provides for the following revisions:

1. HIGHLIGHTS: WARNINGS AND PRECAUTIONS: Thrombotic Microangiopathy – addition of the listing under Recent Major Changes regarding thrombotic microangiopathy, and made editorial changes.
2. Section 5.7 – WARNINGS AND PRECAUTIONS: added thrombotic microangiopathy.
3. Section 5.8, 5.9 – WARNINGS AND PRECAUTIONS: editorial changes made for consistency with text in full prescribing information.
4. Section 6.1 – ADVERSE REACTIONS: added thrombotic microangiopathy.
5. Section 6.2 – ADVERSE REACTIONS: added a) thrombotic microangiopathy b) pancreatitis and c) infections to consistent with listing Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in this section.
6. Section 7 – DRUG INTERACTIONS: editorial changes made for consistency with text in Medication Guide.

SLR-016: Changes Being Effected supplemental drug application provides for the following revision: Revisions to the WARNINGS and PRECAUTIONS section to add increased hepatic monitoring.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alice Kacuba, Chief, Project Management Staff, at (301) 796-1381.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.
Deputy Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S): Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
08/14/2013